Literature DB >> 26646361

Explaining the Better Prognosis of Screening-Exposed Breast Cancers: Influence of Tumor Characteristics and Treatment.

Nathalie J Massat1, Peter D Sasieni1, Daniela Tataru2, Dharmishta Parmar1, Jack Cuzick1, Stephen W Duffy3.   

Abstract

BACKGROUND: In England, population mammographic screening has been offered to women for over 20 years. Overall decrease in breast cancer mortality rates and improvements in cancer awareness and organization of medical care over this period call for a more current evaluation of the mediators behind the better prognosis of screening-exposed breast cancers.
METHODS: A case-control study was conducted within the English National Breast Screening Program. Women who died from primary breast cancer in 2008 to 2009 were matched (by year of birth, screening invitation, and area) to controls that received a diagnosis of invasive breast cancer at the time of the case diagnosis but survived the case death. Data were analyzed by unconditional logistic regression with adjustment for matching factors.
RESULTS: The unadjusted OR for dying from breast cancer associated with ever having attended breast screening was 0.44 [95% confidence interval (CI), 0.33-0.58]. After adjustment for lead time, overdiagnosis, and self-selection, the OR increased to 0.69 (95% CI, 0.50-0.94). Adjusting for tumor size, lymph node status, stage, grade, histopathology, and laterality accounted for all the screening effect (OR, 1.00; 95% CI, 0.71-1.40). Further adjustment for treatment factors only had a minimal impact on the OR (OR, 1.02; 95% CI, 0.72-1.45).
CONCLUSIONS: Our results suggest that earlier diagnosis, as reflected by tumor characteristics, remains the major mediator of the improvement in breast cancer survival due to participation in mammographic screening. IMPACT: Mammographic screening continues to prevent breast cancer-related deaths in the epoch of adjuvant systemic therapy. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 26646361     DOI: 10.1158/1055-9965.EPI-15-0804

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  5 in total

1.  Short- and Long-Term (10-year) Results of an Organized, Population-Based Breast Cancer Screening Program: Comparative, Observational Study from Hungary.

Authors:  Dezső Tóth; Zsolt Varga; Judit Tóth; Péter Árkosy; Éva Sebő
Journal:  World J Surg       Date:  2018-05       Impact factor: 3.352

2.  Impact of Barrett oesophagus diagnoses and endoscopies on oesophageal cancer survival in the UK: A cohort study.

Authors:  Judith Offman; Francesca Pesola; Rebecca C Fitzgerald; Willie Hamilton; Peter Sasieni
Journal:  Cancer Med       Date:  2021-12-16       Impact factor: 4.452

3.  Downregulated circulating microRNAs after surgery: potential noninvasive biomarkers for diagnosis and prognosis of early breast cancer.

Authors:  Yaohui Wang; Wenjin Yin; Yanping Lin; Kai Yin; Liheng Zhou; Yueyao Du; Tingting Yan; Jinsong Lu
Journal:  Cell Death Discov       Date:  2018-08-06

4.  Breast cancer distant recurrence lead time interval by detection method in an institutional cohort.

Authors:  Henry G Kaplan; Judith A Malmgren; Mary K Atwood
Journal:  BMC Cancer       Date:  2020-11-20       Impact factor: 4.430

5.  Recovery of the breast screening programme following pandemic-related delays: Should we focus on round length or uptake?

Authors:  Stephen W Duffy; Sue Hudson; Daniel Vulkan; Thomas E Duffy; Kathie Binysh
Journal:  J Med Screen       Date:  2022-02-04       Impact factor: 1.687

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.